S&P 500 7,498.96 -0.14% NASDAQ 25,690.90 -0.57% DOW 52,218.58 -0.01% R2K 2,959.94 -0.92% VIX 16.64 -2.40% US 10Y 4.66 +0.63% DXY 101.14 -0.04% GOLD 4,128.00 +1.40% CRUDE 87.86 +3.47% BITCOIN 65,990.34 -0.77%
Next Bullish Trade
Sign in
SUPN

Supernus Pharmaceuticals, Inc. NGM · SUPN

$46.94 -0.93 (-1.94%)
Neutral · -0.22σ Grade C
+ Compare Open in Sniper
Mkt cap $2.7B
P/E —
Day $46.81 – $48.12
52wk $42.45 – $59.68
Avg vol 0.8M
Beta 0.54
Div yld —
Next earnings 2026-08-04

Quick read

At a glance

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.

SUPN last traded at $46.94, down 1.9% on the day; that's in the lower part of its 52-week range ($42.45–$59.68). Right now it's trading close to its recent average, with no strong stretch in either direction.

The next scheduled earnings report (2026-08-04) is the biggest known catalyst on the calendar, and day to day, watch whether it holds above or slips below its recent average.

A quick snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

Price is sitting close to its normal range — not meaningfully overheated yet. Plus a bearish engulfing candle — selling fully swallowed the prior bar's buying.

Long —
Setup score 9 / 100
Price is sitting close to its normal range — no real dip to buy yet.
Technical read: above KC1 lower, -0.23 ATR from EMA21 · no notable pattern
What it means: Price is sitting close to its normal range — no real dip to buy yet. The trigger bar shows no standout candle signal yet.
Score split: chart signals 9 / 80 · news & fundamentals checks 0 / 20 — chart signals carry most of the grade.
How this grade was earned
total 9 pts
Cycle position 6
Market fit 3

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short C
Setup score 25 / 100
Price is sitting close to its normal range — not meaningfully overheated yet. bearish engulfing candle.
  • · Bearish engulfing — body fully covers prior green bar
  • · Aligned with weak downtrend
Technical read: below KC1 upper, -0.23 ATR from EMA21 · bearish engulfing
What it means: Price is sitting close to its normal range — not meaningfully overheated yet. The trigger bar shows a bearish engulfing candle — selling fully swallowed the prior bar's buying.
Score split: chart signals 25 / 80 · news & fundamentals checks 0 / 20 — chart signals carry most of the grade.
How this grade was earned
total 25 pts
Cycle position 6
Candle signal 13
Market fit 6

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →
21 EMA +1 ATR +2 ATR −2 ATR
—
O — H — L — C —
— —

Valuation & accounting

Valuation desk →

Our cash-flow model pegs fair value near $132.11 (fair range $31–$132); today's price leaves a +64% cushion below that estimate. The model's verdict is “Deep value” and accounting quality screens as Adequate. Model estimates only — do your own due diligence.

Deep value +64% margin of safety Accounting: Adequate
Intrinsic (DCF)
$132.11
Fair-value range
$31.27 – $132.11
Margin of safety
+64%
Accounting quality Adequate
  • ✓ More cash than debt
  • ✓ Quick ratio 1.69 (antifragile)
  • ✓ Debt/equity 0.37 (antifragile)
  • ✓ Goodwill 9% of assets (organic growth)
  • ⚠ Receivables growing faster than revenue
  • ⚠ Inventory growing faster than revenue

Price implies ~6% growth (vs trailing rev yoy). Model estimate — do your own due diligence.

Key statistics

All statistics →

SUPN is a $2.7 billion company, it moves more calmly than the market (beta 0.5).

Market cap $2.7B
P/E ttm —
Beta 0.54
52w range $42.45 – $59.68
Avg volume 0.8M
Dividend yield —
Sector Healthcare
Next earnings 2026-08-04
52-week range · today's price
$42.45$59.68

More on SUPN

Options idea

See more →
CALL $47 2026-08-21
$2.75
PUT $46 2026-08-21
$2.70

Earnings

See more →
Last reported
2026-05-05
EPS (act / est)
0.21 / 0.28
Surprise
-24.5%
Next report
2026-08-04

About

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa…